Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer

NCT06197438 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

36

Enrollment

OTHER_GOV

Sponsor class

Conditions

Gastric Cancer

Interventions

DRUG: Tislelizumab
DRUG: Oxaliplatin
DRUG: Levo-Leucovorin
DRUG: 5-fluorouracil
DRUG: Irinotecan Hydrochloride
DRUG: Paclitaxel

Sponsor

Fujian Cancer Hospital